Eli Lilly (LLY)

The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older.

Wall Street, according to CNBC's Mad Money host Jim Cramer, is no longer a monolithic entity but rather a fractured landscape operating under three distinct economic realities. In recent broadcasts around October 8 and 9, 2025, Cramer articulated a vision of the market segmented into a booming Artificial Intelligence and

The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.

Is it too late to get on the bandwagon?

This beaten-down drugmaker is well positioned to turn things around.

Now may be the time to invest in drug companies, as they just slipped the tariff noose.

The fallen pharma giant could make a big comeback in 2026.

Investors are excited about the company's weight loss treatments but might be overlooking the exciting pipeline of new therapies.

Investors are eagerly awaiting the start of earnings season for market direction, as the continued government shutdown is creating a lack of economic data

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after a Bank of America report highlighted weakening order trends and a lowered fourth-quarter revenue forecast. 

Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.

This ETF has shown market-beating potential since its inception.

Ongoing developments make these companies look attractive.

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of

Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in understanding the pharmacokinetic profile of this potential therapy. While this marks a technical advancement in drug development, the news

After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.

Roche has a promising GLP-1 drug that is entering phase 3 trials.

Amazon (NASDAQ: AMZN) continues to aggressively expand its strategic business developments, solidifying its e-commerce dominance through frequent Prime discount events and making significant inroads into the pharmacy sector. These initiatives, spanning from late 2023 through 2025, are designed to strengthen customer loyalty, capture new markets, and leverage Amazon's robust logistics

Investors should buy stakes in AI-powered stocks with scalable, asset-light business models.